New Jersey Pharmaceutical Company Settles Case Involving Misrepresenting Drug Pricing Data to Medicare

On March 11, 2015, Sandoz, Inc. (Sandoz), a New Jersey generic pharmaceutical manufacturer, entered into a $12,640,000 settlement agreement with OIG. The settlement agreement resolves allegations that Sandoz misrepresented drug pricing data to the Medicare program. Federal law requires drug makers to report both accurate and timely "Average Sales Price" information to the Centers for Medicare & Medicaid Services (CMS). CMS uses this information to set payment amounts for most drugs covered under Medicare Part B. Inaccurate pricing information can cause Medicare to overpay for these drugs. Senior Counsels Geeta W. Kaveti and Nicole Caucci represented OIG. News Release

Read more on oig.hhs.gov

Share